Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 2
2005 2
2006 3
2007 1
2008 7
2009 15
2010 12
2011 49
2012 45
2013 35
2014 48
2015 82
2016 94
2017 94
2018 117
2019 104
2020 99
2021 122
2022 110
2023 87
2024 82
2025 80
2026 48

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,199 results

Results by year

Filters applied: . Clear all
Page 1
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Schöffski P, et al. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10. Lancet. 2016. PMID: 26874885 Free article. Clinical Trial.
Treatment-emergent adverse events occurred in 224 (99%) of 226 patients who received eribulin and 218 (97%) of 224 who received dacarbazine. Grade 3 or higher adverse events were more common in patients who received eribulin (152 [67%]) than in those who received da …
Treatment-emergent adverse events occurred in 224 (99%) of 226 patients who received eribulin and 218 (97%) of 224 who received dacar …
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Cortes J, et al. Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6. Epub 2011 Mar 2. Lancet. 2011. PMID: 21376385 Clinical Trial.
FINDINGS: 762 women were randomly allocated to treatment groups (508 eribulin, 254 TPC). Overall survival was significantly improved in women assigned to eribulin (median 13.1 months, 95% CI 11.8-14.3) compared with TPC (10.6 months, 9.3-12.5; hazard ratio 0.81, 95% …
FINDINGS: 762 women were randomly allocated to treatment groups (508 eribulin, 254 TPC). Overall survival was significantly improved …
Eribulin.
Perry CM. Perry CM. Drugs. 2011 Jul 9;71(10):1321-31. doi: 10.2165/11207520-000000000-00000. Drugs. 2011. PMID: 21770478 Review.
Eribulin (eribulin mesylate) is a non-taxane microtubule dynamics inhibitor with tubulin-based antimitotic activity and chemotherapeutic effects. ...The most common grade 3/4 adverse events in the eribulin group were neutropenia, leukopenia and asthenia or fa …
Eribulin (eribulin mesylate) is a non-taxane microtubule dynamics inhibitor with tubulin-based antimitotic activity and chemot …
Potential Mechanisms of Interstitial Lung Disease Induced by Antibody-Drug Conjugates Based on Quantitative Analysis of Drug Distribution.
Koganemaru S, Fuchigami H, Morizono C, Shinohara H, Kuboki Y, Furuuchi K, Uenaka T, Doi T, Yasunaga M. Koganemaru S, et al. Mol Cancer Ther. 2025 Feb 4;24(2):242-250. doi: 10.1158/1535-7163.MCT-24-0267. Mol Cancer Ther. 2025. PMID: 39450538 Free PMC article.
The mice received different doses of TROP2-eribulin, a novel TROP2-targeting ADC, composed of an anti-TROP2 antibody and the eribulin payload, joined by a cleavable linker. The concentration and distribution of TROP2-eribulin, as well as the pharmacokinetics …
The mice received different doses of TROP2-eribulin, a novel TROP2-targeting ADC, composed of an anti-TROP2 antibody and the eribu …
Eribulin mesylate.
Jain S, Vahdat LT. Jain S, et al. Clin Cancer Res. 2011 Nov 1;17(21):6615-22. doi: 10.1158/1078-0432.CCR-11-1807. Epub 2011 Aug 22. Clin Cancer Res. 2011. PMID: 21859830 Review.
Eribulin mesylate, a nontaxane, completely synthetic microtubule inhibitor, has recently been approved by the U.S. ...Eribulin significantly increased overall survival (OS; median OS for the eribulin-treated group was 13.1 months versus 10.6 months for the gr …
Eribulin mesylate, a nontaxane, completely synthetic microtubule inhibitor, has recently been approved by the U.S. ...Eribulin …
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Dybdal-Hargreaves NF, et al. Clin Cancer Res. 2015 Jun 1;21(11):2445-52. doi: 10.1158/1078-0432.CCR-14-3252. Epub 2015 Apr 2. Clin Cancer Res. 2015. PMID: 25838395 Free PMC article. Review.
Eribulin mesylate (eribulin), an analogue of the marine natural product halichondrin B, is a microtubule-depolymerizing drug that has utility in the treatment of patients with breast cancer. ...Together, these data highlight the distinct properties of eribulin …
Eribulin mesylate (eribulin), an analogue of the marine natural product halichondrin B, is a microtubule-depolymerizing drug t …
Eribulin-Associated Foot Drop.
Blair TF, Lambert K, Muzaffar M. Blair TF, et al. Am J Ther. 2019 Nov/Dec;26(6):e720-e722. doi: 10.1097/MJT.0000000000000881. Am J Ther. 2019. PMID: 30570505 No abstract available.
An alpha-chloroaldehyde-based formal synthesis of eribulin.
Kaghad A, Panagopoulos D, Caballero-García G, Zhai H, Britton R. Kaghad A, et al. Nat Commun. 2023 Apr 5;14(1):1904. doi: 10.1038/s41467-023-37346-7. Nat Commun. 2023. PMID: 37019928 Free PMC article.
Eribulin (Halaven) is the most structurally complex non-peptidic drug made by total synthesis and has challenged preconceptions of synthetic feasibility in drug discovery and development. However, despite decades of research, the synthesis and manufacture of eribulin …
Eribulin (Halaven) is the most structurally complex non-peptidic drug made by total synthesis and has challenged preconceptions of sy …
Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, Jones RL. Setola E, et al. Expert Rev Anticancer Ther. 2017 Aug;17(8):717-723. doi: 10.1080/14737140.2017.1344098. Epub 2017 Jun 28. Expert Rev Anticancer Ther. 2017. PMID: 28621163 Review.
The potential mechanisms of action of eribulin are also described, including its activity as potent microtubule-destabilizing anticancer agent, which has other antitumor biological effects. Expert commentary: Eribulin is highly effective in some STS populations and …
The potential mechanisms of action of eribulin are also described, including its activity as potent microtubule-destabilizing antican …
Clinical and preclinical features of eribulin-related peripheral neuropathy.
Tarasiuk O, Cavaletti G, Meregalli C. Tarasiuk O, et al. Exp Neurol. 2022 Feb;348:113925. doi: 10.1016/j.expneurol.2021.113925. Epub 2021 Nov 18. Exp Neurol. 2022. PMID: 34801586 Review.
Current clinical evidence suggests that eribulin treatment, unlike some of the other MTAs, is associated with a relatively low incidence of severe peripheral neuropathy. This suggests that different MTAs possess unique mechanisms of neuropathologic induction. Animal models …
Current clinical evidence suggests that eribulin treatment, unlike some of the other MTAs, is associated with a relatively low incide …
1,199 results